GI Signals - IBDhttps://siftingsignal.com/gisignals/IBD papers worth knowing in GI this week. A SiftingSignal publication.Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42462750https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42462750Sat, 18 Jul 2026 20:04:34 +0000The lancet. Gastroenterology & hepatology. Consider duvakitug 900 mg every 2 weeks for adults aged 18-75 with moderately to severely active ulcerative colitis, including those with inadequate response, loss of response, or intolerance to prior therapies, while monitoring for adverse events.Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-41784159https://siftingsignal.com/gisignals/2026-W26/#card-pmid-41784159Thu, 09 Jul 2026 16:47:07 +0000Inflammatory bowel diseases. Disability is common in IBD and persists even in remission (about 27 percent), so consider periodically assessing it with a validated tool (IBD Disk or IBD-Disability Index) rather than assuming remission equals full function.Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42030468https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42030468Thu, 09 Jul 2026 16:47:07 +0000Inflammatory bowel diseases. A Bayesian meta-analysis suggests intensified infliximab induction may lower early colectomy in acute severe UC, but the only randomized trial (PREDICT-UC 2024) showed no benefit, so intensification remains non-standard and best individualized (e.g. high-clearance or hypoalbuminemic patients) rather than applied routinely.Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42118952https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42118952Thu, 09 Jul 2026 16:47:07 +0000Inflammatory bowel diseases. SB012, a GATA3-targeting DNAzyme enema, showed an early efficacy signal in a small phase 2a UC trial but is investigational and not clinically available, so no practice change pending larger trials.ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413123https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42413123Thu, 09 Jul 2026 16:47:07 +0000Journal of Crohn's & colitis. Use ECCO UC therapeutics for the European perspective, but reconcile positioning against US ACG and AGA guidance and FDA safety labeling (notably the JAK-inhibitor boxed warning: age 50 or older with a cardiovascular risk factor, use after anti-TNF failure) before applying.ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42417116https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42417116Thu, 09 Jul 2026 16:47:07 +0000Journal of Crohn's & colitis. Before or early in immunosuppressive or biologic therapy for IBD, complete an infection-prevention bundle: screen for latent TB and hepatitis B, check VZV and measles immunity, and vaccinate (recombinant zoster for immunosuppressed adults, updated pneumococcal schedule, annual influenza, COVID), avoiding live vaccines during active immunosuppression.